KU-55933 (ATM Kinase Inhibitor)

Name: KU-55933 (ATM Kinase Inhibitor)
Brand: Selleck Chemicals
SKU: S1092
Rating: 5 (222 reviews)

For research use only.

Catalog No.S1092

222 publications

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

CAS No. 587871-26-9

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/K_i of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR. KU‑55933 (ATM Kinase Inhibitor) inhibits the activation of autophagy‑initiating kinase ULK1 and results in a significant decrease of autophagy.

Selleck's KU-55933 (ATM Kinase Inhibitor) has been cited by 222 publications

Cancer Cell, 2021, S1535-6108(20)30658-9

PubMed: 33450196 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 560(7716):112-116

PubMed: 30022158 ( click the link to review the publication )

Cancer Cell, 2017, 32(3):342-359

PubMed: 28898696 ( click the link to review the publication )

Science, 2016, 352(6283):353-8

PubMed: 27013428 ( click the link to review the publication )

Nature, 2015, 528(7582):422-6

PubMed: 26649820 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14328

PubMed: 25799992 ( click the link to review the publication )

Cell, 2013, 155(5):1088-103

PubMed: 24267891 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1048-63

PubMed: 22915751 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(20)30951-5

PubMed: 33453166 ( click the link to review the publication )

Nucleic Acids Res, 2021, gkaa1290

PubMed: 33469661 ( click the link to review the publication )

J Cell Biol, 2021, 220(2)e201807163

PubMed: 33404608 ( click the link to review the publication )

Carcinogenesis, 2021, bgab002

PubMed: 33417668 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(20):2000157

PubMed: 33101843 ( click the link to review the publication )

Mol Cell, 2020, S1097-2765(20)30723-1

PubMed: 33152268 ( click the link to review the publication )

Mol Cell, 2020, 22 pii: S1097-2765(20)30231-8

PubMed: 32353258 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6178

PubMed: 33268790 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

Nat Commun, 2020, 26;11(1):2641

PubMed: 32457376 ( click the link to review the publication )

Nat Commun, 2020, 8;11(1):2876

PubMed: 32513994 ( click the link to review the publication )

Nucleic Acids Res, 2020, 6;48(6):2982-3000

PubMed: 31970415 ( click the link to review the publication )

Cell-Rep, 2020, 18;30-7-:2402-2415-e5

PubMed: 32075772 ( click the link to review the publication )

Cell Rep, 2020, 18;30(7):2083-2093 e5

PubMed: 32075732 ( click the link to review the publication )
Cell Rep, 2020, 14;31(2):107518

PubMed: 32294440 ( click the link to review the publication )

Cell Rep, 2020, 32(9):108080

PubMed: 32877684 ( click the link to review the publication )

Cell Rep, 2020, 31(10):107745

PubMed: 32521270 ( click the link to review the publication )

Elife, 2020, 30;9:e51466

PubMed: 32223892 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 77(4):735-749

PubMed: 31297568 ( click the link to review the publication )

mBio, 2020, 11(1)

PubMed: 32071277 ( click the link to review the publication )

mBio, 2020, 11(3):e01190-20

PubMed: 32546626 ( click the link to review the publication )

Cancers (Basel), 2020, 28;12(6):E1388

PubMed: 32481544 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2467

PubMed: 32878283 ( click the link to review the publication )

PLoS Pathog, 2020, 16(6):e1008514

PubMed: 32479542 ( click the link to review the publication )

Arterioscler Thromb Vasc Biol, 2020, ATVBAHA120315206

PubMed: 33356386 ( click the link to review the publication )

Arch Toxicol, 2020, 10.1007/s00204-020-02712-7

PubMed: 32189037 ( click the link to review the publication )

Mol Oncol, 2020, 26

PubMed: 32336009 ( click the link to review the publication )

Aging (Albany NY), 2020, 22;12(6):4688-4710

PubMed: 32201398 ( click the link to review the publication )

DNA Repair (Amst), 2020, 87:102803

PubMed: 31991288 ( click the link to review the publication )

Sci Rep, 2020, 10(1):14455

PubMed: 32879366 ( click the link to review the publication )

Cell Mol Biol Lett, 2020,

PubMed: 32874188 ( click the link to review the publication )

PLoS One, 2020, 15(1):e0223463

PubMed: 31914134 ( click the link to review the publication )

Int J Radiat Biol, 2020, 96(4):461-468

PubMed: 31859574 ( click the link to review the publication )

Sci Rep, 2020, 10(1):2200

PubMed: 32042076 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):1490

PubMed: 32517381 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2356

PubMed: 32825402 ( click the link to review the publication )

Nat Chem Biol, 2020, 10.1038/s41589-020-0600-3

PubMed: 32719556 ( click the link to review the publication )

J Biol Chem, 2020, 295(1):125-137

PubMed: 31753920 ( click the link to review the publication )
Nat Commun, 2020, 11(1):123

PubMed: 31913317 ( click the link to review the publication )

Med Mol Morphol, 2020, 10.1007/s00795-020-00264-4

PubMed: 32816116 ( click the link to review the publication )

Mol Cell, 2019, 75(6):1299-1314

PubMed: 31353207 ( click the link to review the publication )

Mol Cell, 2019, 74(4):651-663.e8

PubMed: 30954402 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2910

PubMed: 31266951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1577

PubMed: 30952868 ( click the link to review the publication )

Nat Commun, 2019, 10(1):87

PubMed: 30622252 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz518

PubMed: 31184714 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-3388

PubMed: 31515237 ( click the link to review the publication )

J Cell Biol, 2019, 218(7):2113-2123

PubMed: 31123184 ( click the link to review the publication )

Cell Rep, 2019, 26(8):2194-2211.e6

PubMed: 30784599 ( click the link to review the publication )

Cell Rep, 2019, 28(3):735-745

PubMed: 31315051 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0393-7

PubMed: 31320750 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31766690 ( click the link to review the publication )

Cancer Discov, 2019, 9(9):1306-1323

PubMed: 31217297 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 21(12):1143-1150

PubMed: 31759252 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:8535163

PubMed: 31641425 ( click the link to review the publication )

J Cell Physiol, 2019, 234(11):21294-21306

PubMed: 31054162 ( click the link to review the publication )

J Virol, 2019, 93(14)

PubMed: 31043526 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13097

PubMed: 31511540 ( click the link to review the publication )

J Biol Chem, 2019, 294(17):7037-7045

PubMed: 30858175 ( click the link to review the publication )

J Biol Chem, 2019, 294(8):2827-2838

PubMed: 30598506 ( click the link to review the publication )
Retrovirology, 2019, 16(1):13

PubMed: 31036006 ( click the link to review the publication )

Sci Adv, 2019, 5(3):eaav1118

PubMed: 30944854 ( click the link to review the publication )

Sci Adv, 2019, 5(5):eaav3235

PubMed: 31086816 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.215210

PubMed: 31727767 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(10):5243-5259

PubMed: 30976812 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2019, 105(4):861-874

PubMed: 31419512 ( click the link to review the publication )

J Exp Med, 2019, 216(7):1648-1663

PubMed: 31097467 ( click the link to review the publication )

J Pineal Res, 2019, 67(4):e12603

PubMed: 31370106 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(4):413-421

PubMed: 29531308 ( click the link to review the publication )

Cell Res, 2018, 28(7):756-770

PubMed: 29844578 ( click the link to review the publication )

Mol Cell, 2018, 71(2):332-342

PubMed: 30017584 ( click the link to review the publication )

Mol Cell, 2018, 69(5):879-892.e5

PubMed: 29478807 ( click the link to review the publication )

Nat Struct Mol Biol, 2018, 25(3):261-269

PubMed: 29483652 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5351

PubMed: 30559436 ( click the link to review the publication )

Nat Commun, 2018, 9(1):697

PubMed: 29449575 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1317

PubMed: 29615613 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(19):10119-10131

PubMed: 30165463 ( click the link to review the publication )

Sci Adv, 2018, 4(12):eaat5077

PubMed: 30585287 ( click the link to review the publication )

Cancer Res, 2018, 78(18):5363-5374

PubMed: 30054334 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3393-3403.e5

PubMed: 30257201 ( click the link to review the publication )

Int J Cancer, 2018,

PubMed: 29363109 ( click the link to review the publication )

Redox Biol, 2018, 14:645-655

PubMed: 29172151 ( click the link to review the publication )
Cancer Lett, 2018, 419:280-290

PubMed: 29378238 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):164

PubMed: 29415984 ( click the link to review the publication )

Cell Death Dis, 2018, 9(6):660

PubMed: 29855474 ( click the link to review the publication )

FASEB J, 2018, 32(4):1818-1829

PubMed: 29162700 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(23):4024-4035

PubMed: 30107443 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(10):1645-1660

PubMed: 29849127 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 39(12):1874-1884

PubMed: 29921885 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):709-720

PubMed: 29328365 ( click the link to review the publication )

Virology, 2018, 523:121-128

PubMed: 30119013 ( click the link to review the publication )

Arch Biochem Biophys, 2018, 644:93-99

PubMed: 29352966 ( click the link to review the publication )

Transl Oncol, 2018, 11(4):988-998

PubMed: 29940414 ( click the link to review the publication )

Oncol Rep, 2018, 39(5):2071-2080

PubMed: 29565449 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2363-2370

PubMed: 30066882 ( click the link to review the publication )

Radiat Res, 2018, 189(5):505-518

PubMed: 29474155 ( click the link to review the publication )

Oncol Lett, 2018, 16(5):6608-6614

PubMed: 30405800 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(9):1697-1711

PubMed: 30323964 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(16):8311-8325

PubMed: 30010936 ( click the link to review the publication )

Blood, 2017, 129(21):2882-2895

PubMed: 28283481 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2039

PubMed: 29229926 ( click the link to review the publication )

EMBO J, 2017, 2;36(9):1261-1278

PubMed: 28320736 ( click the link to review the publication )

Genes Dev, 2017, 31(7):648-659

PubMed: 28446595 ( click the link to review the publication )

Genes Dev, 2017, 31(3):318-332

PubMed: 28242626 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4567-4578

PubMed: 28698210 ( click the link to review the publication )
J Cell Biol, 2017, 216(3):623-639

PubMed: 28228534 ( click the link to review the publication )

EMBO Rep, 2017, 18(5):781-796

PubMed: 28325772 ( click the link to review the publication )

Cancer Lett, 2017, 390:48-57

PubMed: 28093285 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):133

PubMed: 28950914 ( click the link to review the publication )

Free Radic Biol Med, 2017, 108:750-759

PubMed: 28431961 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e3019

PubMed: 28837154 ( click the link to review the publication )

Cell Death Dis, 2017,

PubMed: 28518141 ( click the link to review the publication )

Stem Cells Transl Med, 2017, 6(6):1504-1514

PubMed: 28544661 ( click the link to review the publication )

Sci Total Environ, 2017, 1599:375-390

PubMed: 28477133 ( click the link to review the publication )

Sci Rep, 2017, 7(1):16115

PubMed: 29170437 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12424-12435

PubMed: 28592488 ( click the link to review the publication )

Int J Oncol, 2017, 50(1):290-296

PubMed: 27959407 ( click the link to review the publication )

Eur J Pharm Sci, 2017, 109:223-232

PubMed: 28822757 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Virology, 2017, 510:9-21

PubMed: 28689087 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):338

PubMed: 28521819 ( click the link to review the publication )

Oncol Rep, 2017, 38(1):591-597

PubMed: 28560404 ( click the link to review the publication )

PLoS One, 2017, 12(7):e0181530

PubMed: 28746371 ( click the link to review the publication )

Nutr Cancer, 2017, 69(8):1281-1289

PubMed: 29111814 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(18):10564-10582

PubMed: 28985345 ( click the link to review the publication )

Genome Biol, 2017, 18(1):224

PubMed: 29178945 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1357-1366

PubMed: 27820601 ( click the link to review the publication )

Mol Cell, 2016, 61(3):405-418

PubMed: 26774285 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(10):4745-62

PubMed: 26939887 ( click the link to review the publication )
Genes Dev, 2016, 30(3):321-36

PubMed: 26833731 ( click the link to review the publication )

J Cell Biol, 2016, 212(4):399-408

PubMed: 26880199 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.15129

PubMed: 27269284 ( click the link to review the publication )

Cell Death Discov, 2016, 2:16011

PubMed: 27551505 ( click the link to review the publication )

Cell Death Discovery, 2016, 10.1038/cddiscovery.2016.11

PubMed: ( click the link to review the publication )

FASEB J, 2016, 30(8):2899-914

PubMed: 27142525 ( click the link to review the publication )

Oxid Med Cell Longev, 2016, 2016:4313204

PubMed: 28042385 ( click the link to review the publication )

Cell Discov, 2016, 2:16016

PubMed: 27462463 ( click the link to review the publication )

J Immunol, 2016, 197(7):2918-29

PubMed: 27559048 ( click the link to review the publication )

J Cell Sci, 2016, 129(16):3167-77

PubMed: 27383768 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 292:65-74

PubMed: 26708502 ( click the link to review the publication )

Chem Res Toxicol, 2016, 29(1):26-39

PubMed: 26630137 ( click the link to review the publication )

Cell Cycle, 2016, 15(1):84-94

PubMed: 26771713 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):725

PubMed: 27613518 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2016, 77(1):169-80

PubMed: 26590990 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0167454

PubMed: 27907109 ( click the link to review the publication )

Oncotarget, 2016, 7(38):60807-60822

PubMed: 27602502 ( click the link to review the publication )

Sci Rep, 2016, 6:27379

PubMed: 27271479 ( click the link to review the publication )

Oncotarget, 2016, 7(20):29359-70

PubMed: 27121065 ( click the link to review the publication )

Oncotarget, 2016, 7(31):49800-49818

PubMed: 27391441 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(8):1004-13

PubMed: 26214134 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(11):1446-57

PubMed: 26502055 ( click the link to review the publication )

Leukemia, 2015, 29(5):1133-42

PubMed: 25371178 ( click the link to review the publication )

Genes Dev, 2015, 29(11):1151-63

PubMed: 26019174 ( click the link to review the publication )
Nanoscale, 2015, 7(47):20211-9

PubMed: 26575637 ( click the link to review the publication )

Oncogene, 2015, 34(23):2978-90

PubMed: 25132270 ( click the link to review the publication )

Arch Toxicol, 2015, 89(11):2015-25

PubMed: 25294323 ( click the link to review the publication )

PLoS Genet, 2015, 11(10):e1005563

PubMed: 26430909 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(5):1649-64

PubMed: 26175935 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: ( click the link to review the publication )

Mol Cancer Res, 2015, 13(1):120-9

PubMed: 25232030 ( click the link to review the publication )

Sci Rep, 2015, 5:11465

PubMed: 26095524 ( click the link to review the publication )

Cell Signal, 2015, 27(5):951-60

PubMed: 25683911 ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(11):1585-92

PubMed: 26382920 ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(20):3248-60

PubMed: 26312527 ( click the link to review the publication )

Cell Cycle, 2015, 14(4):648-55

PubMed: 25590338 ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142561

PubMed: 26556501 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0145994

PubMed: 26717578 ( click the link to review the publication )

Int J Radiat Biol, 2015, 10.3109/09553002.2015.1029595

PubMed: 25912236 ( click the link to review the publication )

Cell Biol Int, 2015, 10.1002/cbin.10439

PubMed: 25598069 ( click the link to review the publication )

Anticancer Res, 2015, 35(7):3829-38

PubMed: 26124328 ( click the link to review the publication )

Nat Neurosci, 2014, 17(6):813-21

PubMed: 24793032 ( click the link to review the publication )

Cell Death Differ, 2014, 10.1038/cdd.2014.159

PubMed: 25301067 ( click the link to review the publication )

Mol Cancer, 2014, 13:36

PubMed: 24568192 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.268

PubMed: 25132265 ( click the link to review the publication )

Cancer Discov, 2014, 4(10):1198-213

PubMed: 25100205 ( click the link to review the publication )

DNA Repair , 2014, 21:140-7

PubMed: 24795278 ( click the link to review the publication )
Biochim Biophys Acta, 2014, 1843(5):934-44

PubMed: 24480460 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1842(7):1071-9

PubMed: 24726882 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1842(7):1088-96

PubMed: 24726884 ( click the link to review the publication )

J Biol Chem, 2014, 289(23):16072-84

PubMed: 24782314 ( click the link to review the publication )

Toxicol Appl Pharm, 2014, 282(2):227-236

PubMed: 25450480 ( click the link to review the publication )

Cell Cycle, 2014, 13(11):1777-87

PubMed: 24732096 ( click the link to review the publication )

Neurotox Res, 2014, 25(2):193-207

PubMed: 23996700 ( click the link to review the publication )

Radiat Res, 2014, 181(6):650-8

PubMed: 24785587 ( click the link to review the publication )

Theriogenology, 2014, 12(5):e1001856

PubMed: 24800743 ( click the link to review the publication )

Proteomes, 2014, 2, 451-467

PubMed: ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Proteomes, 2014, 2(3):451-467

PubMed: 28250390 ( click the link to review the publication )

PLoS One, 2014, 9(6):e98891

PubMed: 24902048 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10157-69

PubMed: 24021630 ( click the link to review the publication )

Sci Signal, 2013, 6(259):ra5

PubMed: 23354688 ( click the link to review the publication )

Neurotox Res, 2013, 25(2):193-207

PubMed: 23996700 ( click the link to review the publication )

FEBS Lett, 2013, 587(21):3437-43

PubMed: 24021642 ( click the link to review the publication )

PLoS One, 2013, 9(1):e84899

PubMed: 24454762 ( click the link to review the publication )

PLoS One, 2013, 8(11):e80313

PubMed: 24282534 ( click the link to review the publication )

J Gen Virol, 2013, 94(Pt 12):2664-2669

PubMed: 24045107 ( click the link to review the publication )

Cell Cycle, 2013, 12(7):1105-18

PubMed: 23462183 ( click the link to review the publication )

Autophagy, 2012, 8(2):236-51

PubMed: 22240589 ( click the link to review the publication )

J Immunol, 2012, 188(5):2266-75

PubMed: 22287717 ( click the link to review the publication )

J Biol Chem, 2012, 287(26):22112-22

PubMed: 22566699 ( click the link to review the publication )
J Biol Chem, 2012, 287(12):8803-15

PubMed: 22270370 ( click the link to review the publication )

Food Chem Toxicol, 2012, 55:214-21

PubMed: 23274058 ( click the link to review the publication )

Int J Radiat Biol, 2012, 88(7):507-14

PubMed: 22449004 ( click the link to review the publication )

J Virol, 2011, 85(23):12547-56

PubMed: 21917957 ( click the link to review the publication )

J Biol Chem, 2011, 286(10):8394-404

PubMed: 21148313 ( click the link to review the publication )

Mech Ageing Dev, 2011, 132(11-12):543-51

PubMed: 21945951 ( click the link to review the publication )

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description

Targets

ATM ^[1]
(Cell-free assay)

12.9 nM

In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. ^[1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
DU-145	NF\nfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\XcoJKSzVyPUOuNlc{PTJizszN	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
HuO-3N1	NGP5WY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTRwMUexOFIh\|ryP	NULUWZd6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
LAMA-84	MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTRwNUi0OlUh\|ryP	NGnyTHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
CAL-72	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVLrdYRVUUN3ME21MlQ5ODh2IN88US=>	NFW2cVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
LoVo	NVyxc5F4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nLTGlEPTB;Nj65N\|I{QSEQvF2=	NGj5VW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HH	Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHr2OFBKSzVyPUiuNlc3PzFizszN	NVrTNoVRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
SK-MEL-3	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXqwUFQ2UUN3ME24MlI5PTd3IN88US=>	M2rlRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
KM12	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LmTmlEPTB;OT6yNVE1OiEQvF2=	M1fuVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
NCI-H1437	NFLyTnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{O4R2lEPTB;OT64NFk4KM7:TR?=	NHjYelI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
NCI-H1838	NW[4NYtrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzQZZg2UUN3ME2xNU4yQDZ3IN88US=>	M3;YRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
J-RT3-T3-5	M3PIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{O2ZWlEPTB;MUGuNlQyPyEQvF2=	M3e5c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
GOTO	MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFmwWYtKSzVyPUGxMlY6QTZizszN	NH3veIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
LB2241-RCC	NYC2TW9sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjkOmtKSzVyPUGxMlcyQDZizszN	M{HoT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
ES7	NWTvUZIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTFzLke4PEDPxE1?	NXH1XXQ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
KP-N-YS	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlP2TWM2OD1zMj62N\|U1KM7:TR?=	NX\GVZp6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
CAL-12T	NFe2dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTF\|Lk[xO{DPxE1?	Mmi5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
COLO-684	Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXP3PZBXUUN3ME2xOE4yPTZ7IN88US=>	M4q0WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
DOK	MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTF3LkOzNlkh\|ryP	NG\OV3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
Hs-578-T	NGDlcVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3v2cmlEPTB;MUWuOFE5OiEQvF2=	MnTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
D-423MG	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHnfHBKSzVyPUG1MlUzOzZizszN	NHzrZ2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
DBTRG-05MG	MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfBTmNKSzVyPUG1MlYyOTFizszN	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
VM-CUB-1	NGfJNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYi2ZnBiUUN3ME2xOU46QDR7IN88US=>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
KG-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\zbmlEPTB;MU[uNFk6PiEQvF2=	NHjPSWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
8305C	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTF4LkG4PFkh\|ryP	NF3IXXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HuH-7	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVTJR\|UxRTF4LkK2O\|Qh\|ryP	NHvFU2w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
LXF-289	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXHDN\|lmUUN3ME2xOk4zPzR5IN88US=>	NGH0bHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
NCI-H1793	MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTF4LkS3NVIh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
ChaGo-K-1	M1vJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmOzTWM2OD1zNj62OVY5KM7:TR?=	NWDHS5VERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
GCIY	Mly5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moe3TWM2OD1zNj63PVA2KM7:TR?=	M2rBXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
SK-MEL-28	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHGyem1KSzVyPUG3MlA1PzVizszN	MkHCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NCI-SNU-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4Tu[mlEPTB;MUeuNVI3QSEQvF2=	M3fIVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
CTB-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojuTWM2OD1zNz6yNlU6KM7:TR?=	MkDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NCI-H82	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU[4SItZUUN3ME2xO{41PTd\|IN88US=>	M4C4V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
HCC2998	MmnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3WfGhMUUN3ME2xO{43PzN\|IN88US=>	M{i4TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
NCI-H2030	NGDVOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HY[2lEPTB;MUiuNVk6PyEQvF2=	NXjQcphtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
HuP-T3	MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPRXHZKSzVyPUG4MlU5QDhizszN	M{LzUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
697	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoP6TWM2OD1zOT6wNlAyKM7:TR?=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
MLMA	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTF7LkC1OVch\|ryP	MnjBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
HCC70	NIj6eolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml23TWM2OD1zOT60PFkh\|ryP	NVWxdXZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
A704	MnjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTF7LkizNFUh\|ryP	MlPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
D-283MED	MnzIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEmxdVFKSzVyPUKwMlU{OzlizszN	M4\xPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
U031	M1rST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmjtTWM2OD1{MT6xOFg6KM7:TR?=	M2rlUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
HSC-3	M1frSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTqS\|BuUUN3ME2yNU4yQDN3IN88US=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
JVM-3	NWr5OIpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTJ{LkWwOkDPxE1?	NV6xXGgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
Mewo	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7nTWM2OD1{Mj61NFc{KM7:TR?=	NI\FfnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
YH-13	NX20dpFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2DEVmlEPTB;MkKuOVEzOyEQvF2=	M4G4SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
LB1047-RCC	M1jq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILIXnhKSzVyPUKyMlU5PzlizszN	NFzsbZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HCC2157	M2HaVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfXOlJ{UUN3ME2yNk45ODV2IN88US=>	MmmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
SNU-449	NEm3WW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXJbmJKSzVyPUKyMlg4PDhizszN	NVfCXXFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
Ramos-2G6-4C10	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHtTWM2OD1{Mj65OkDPxE1?	M3mxRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
CHL-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFW1bpFKSzVyPUKzMlczQTJizszN	NGewd489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
SK-MEL-30	NF3T[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjhVJJoUUN3ME2yOE41PjZ{IN88US=>	M1v3dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
PANC-08-13	NXHn[GtxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPuNmd6UUN3ME2yOU4xQTN6IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
QIMR-WIL	M{TTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFW5c\|RKSzVyPUK1MlE5PThizszN	NXnR[mVIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
BFTC-905	NWLmW5liT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjXcGFSUUN3ME2yOU42QTR2IN88US=>	NYPQZodiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
GI-1	M2KwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mni0TWM2OD1{NT63NFU2KM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
MDA-MB-415	M1HO[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTJ4LkWwN\|Mh\|ryP	NGnYVmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
GT3TKB	MlnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnXOIpKSzVyPUK2MlU{PDJizszN	M3rjb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
DEL	MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorPTWM2OD1{Nj64N\|U3KM7:TR?=	NELvT3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
KOSC-2	Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\LU4JKSzVyPUK2MlkxPzVizszN	MlHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
RVH-421	Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXobHpTUUN3ME2yO{4zQTJzIN88US=>	M1[3fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
EW-13	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFO2THJKSzVyPUK3MlQ{ODhizszN	NVHPc\|JpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
639-V	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrXTWM2OD1{Nz61NVE6KM7:TR?=	MnzsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
A2780	NWnPXJpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGq3PYtKSzVyPUK3MlY1OSEQvF2=	M1\WdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
SW982	NV;IbVBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37QOGlEPTB;MkeuPVA2OiEQvF2=	NYfIcFQzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
SW1710	M1n3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fWZ2lEPTB;MkiuNFk5OSEQvF2=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
HCC1569	MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3Se4VpUUN3ME2yPE41QDl5IN88US=>	Ml\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
MV-4-11	MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTpTWM2OD1{OD61O\|M2KM7:TR?=	NWL0eXViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
BHT-101	NUPXWIVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTJ6Lk[1O\|Ih\|ryP	NGTZbGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
Ca9-22	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1faXWlEPTB;MkiuO\|E1KM7:TR?=	M4X4S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
HAL-01	M{fIT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTJ6Lke2NVUh\|ryP	M2rnPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
D-263MG	NIe3WGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXrcJFHUUN3ME2yPU4{PDRizszN	Moe0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NEC8	NWTiOYxLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHkc5FGUUN3ME2yPU42PTR6IN88US=>	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
EKVX	M4PNfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnO4TWM2OD1\|MT61PFQ4KM7:TR?=	MmTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
EM-2	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XxeGlEPTB;M{GuOlMxPCEQvF2=	NVXjNJZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
MFM-223	M2\EeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTxTFB5UUN3ME2zNU45ODl6IN88US=>	NVLhOXQxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
SK-PN-DW	NUPxNXpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3v[HY{UUN3ME2zNk4yPDB4IN88US=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
HuO9	NHXBV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIO3UIxKSzVyPUOyMlUzQDJizszN	M4CyeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
MHH-PREB-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTN{Lk[yN\|Qh\|ryP	M{XxdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
OVCAR-4	Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfSTWM2OD1\|Mj64N\|Y{KM7:TR?=	NV25RZJPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
NCI-H1648	NVznfYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\kWWpSUUN3ME2zNk45PjVzIN88US=>	NX7XO3R2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
MKN1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTN2LkGxNFEh\|ryP	NFPTbVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
KYSE-450	NV7IT\|lMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnkfGtbUUN3ME2zOE43PDR2IN88US=>	NH7pcXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
ES8	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTN2Lki5O\|Uh\|ryP	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
MS-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTN2Lkm1OVQh\|ryP	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
HOP-92	Mn;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLwcmdKSzVyPUO1MlkzPzdizszN	NXnxeIFORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
SKG-IIIa	Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTN4LkK1OlEh\|ryP	M1jnNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
TE-11	NELT[ppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoniTWM2OD1\|Nj61NlQ{KM7:TR?=	NH;MOGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
SK-NEP-1	M3LOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTvTWM2OD1\|Nz62O\|Q1KM7:TR?=	MlnhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
DB	M1;BPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXZOnZKSzVyPUO3MlkyQDVizszN	NHL3SYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
IA-LM	M3uzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3JTWM2OD1\|OD6wNlM6KM7:TR?=	NHjsPJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
COLO-829	MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPFTWM2OD1\|OD60NVU6KM7:TR?=	NV;4eYYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
TGBC11TKB	M1nGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\1PVJqUUN3ME2zPU4yPDB6IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
CAL-51	MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvvbG9FUUN3ME20NE4xPjF{IN88US=>	MkjnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NCI-H2228	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXPZPIZQUUN3ME20NE4{PjZ{IN88US=>	NXTFW4tvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
C32	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnFTWM2OD12MD60NFI1KM7:TR?=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
KU-19-19	NUG0e3lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTLTWM2OD12MD63Olg{KM7:TR?=	M2XrSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
KNS-62	NEjmSZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYq5TYNwUUN3ME20NE45OzhzIN88US=>	NV\a[od6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
FADU	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTRzLkK1NFIh\|ryP	M3rFVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
CAL-33	M3\afWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vUR2lEPTB;NEKuOlc1QSEQvF2=	M4TpZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
CHP-134	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTR{Lki0PVYh\|ryP	M2m2WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
HDLM-2	Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PlXWlEPTB;NEKuPVA5PCEQvF2=	NXyxTWY5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
NBsusSR	NIT1R2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LvU2lEPTB;NEOuNFczPSEQvF2=	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
SW954	M2TuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTR\|LkGwOVMh\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
HCC1806	M{XOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXEZlJKSzVyPUSzMlQyOSEQvF2=	MkfzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
VMRC-RCZ	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTR\|LkS1PFYh\|ryP	MkLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
A549	MkDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPSW\|VDUUN3ME20N{46OzFizszN	MoLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NKM-1	M4rmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWroZotpUUN3ME20N{46PTV6IN88US=>	M4LTVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
DMS-273	NUjncY1JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjFeXFKSzVyPUS0Mlc2PjdizszN	NXGwZYY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
TYK-nu	MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPhd4c1UUN3ME20OU4yOjN2IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
KALS-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPuTWM2OD12NT6xOFYh\|ryP	NFixR5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
A101D	MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoH5TWM2OD12NT60OFU3KM7:TR?=	NH7wR2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
G-361	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rWbWlEPTB;NE[uNlE{QCEQvF2=	NFnxbZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
KARPAS-299	Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3rfm57UUN3ME20Ok4{PTF4IN88US=>	MlTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
RS4-11	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTR4LkW0NkDPxE1?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
HT-1376	Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTR4Lke0NlYh\|ryP	NXzQbFRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
SK-N-AS	NEm1OVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmH2TWM2OD12Nj63PFIzKM7:TR?=	NUPWOnZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOjJ{MUCyM{c,W0GQR1XSQE9iRg>?
MG-63	M333O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrVTWM2OD12Nj65NFM3KM7:TR?=	M2\SPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFIzOjFyMj:nQnNCVkeHUkyvZV4>
EPLC-272H	M1vHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfHZZhvUUN3ME20Ok46PTB\|IN88US=>	MlnCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
BALL-1	MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\XdmlEPTB;NEeuPFMzKM7:TR?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
LCLC-97TM1	NWLDU3dXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTR6LkKwNkDPxE1?	NELsTpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwzOjJzMEKvK\|5USU6JRWK8M4E,
HO-1-N-1	Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnUeHZ7UUN3ME20PE46Pjd4IN88US=>	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
MFE-280	NXXEUpN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzCTWM2OD12OT60OlE4KM7:TR?=	MmXpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
NCI-H526	M3Pw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonETWM2OD12OT64NVY{KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyyNlIyODJxJ{7TRW5ITVJ:L3G+
D-566MG	NEXHOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MorqTWM2OD12OT65NFk3KM7:TR?=	MkTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
BB30-HNC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTR7Lkm0PVgh\|ryP	MlnGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
SK-N-DZ	MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\iNGlEPTB;NUCuNFQ5OSEQvF2=	MkLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNlIzOTB{Lze+V2FPT0WUPD;hQi=>
HepG2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHfGRmEyOMLizszN	NF[4ZmMzPCCq		NV7xVlVJ[myxY3vzJHNENUmLSUOtbY5lfWOnZDDTJJBp[XOnIHHydoV{fA>?	MmjHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkexNlMoRjJ3NUK3NVI{RC:jPh?=
HepG2	MnPTSpVv[3Srb36gRZN{[Xl?	NWfGTI1[OTEEoN88US=>	MljpNlQhcA>?		NHr4U4p{fXCycnXzd4V{KHSqZTDwbI9{eGixconsZZRqd26\|IH;mJGFVVSCxbjDT[ZIyQThzLDDDbIsyKG:wIGPldlM1PSxiQ3jrNkBwdiCWaIK2PEwh[W6mIFPkb\|Ihd25iVInyNVUhcW6mdXPl[EBjgSCVQz3JTWk{	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{N{GyN{c,OjV3MkexNlM9N2F-
KATO III	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfW[Y4zNjVxNT:3MlUh\|ryP		NHn0WItFVVOR	NV;jXVVI\W6qYX7j[ZMhfGinIITvfIlkcXS7IH;mJI9t[XCjcnni	MlPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NEG3NVgoRjJ2OESxO\|E5RC:jPh?=
hTCEpi	NWXoSIlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofWNVAh\|ryP		M373PWROW09?	MnrGdJJmfmWwdIOgeIhmKGO7dH;wZZRpcWNiZX\m[YN1KG:oIFjTWk0y	NGfNOIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO3NFg{PSd-MkSzO\|A5OzV:L3G+
MCF10A	MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX6xNEDPxE1?	M2P5eVI1KGh?	MVLEUXNQ	NUfRfWRDeG:2ZX70bYF1\XNidHjlJIN6fG:2b4jpZ4l1gSCxZjDHRS=>	NXfUUHFmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOVA2QTVpPkK0NVUxPTl3PD;hQi=>
HL-60	Mlj1SpVv[3Srb36gRZN{[Xl?	MkG0NVAh\|ryP	NEf4UVExNjViaB?=	NIHVZnhFVVOR	NVXWTG5wemWmdXPld{BxcG:\|cHjvdplt[XSrb36gc4YhS2itMtMg	M{PMdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUO0OFEyLz5{M{mzOFQyOTxxYU6=
MCF-7	MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWixMVExOM7:TR?=	MWGyOEBp	M{PMdGZDWw>?	NVz4U3RVcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?=	MmjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNzOEWzOFcoRjJ\|MUi1N\|Q4RC:jPh?=
HeLa	MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1GwUlEuOTByzszN	MVmyOEBp	NG\wfGdHSlN?	M{fz[olvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25?	M{TqcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MUi1N\|Q4Lz5{M{G4OVM1PzxxYU6=
SH-SY5Y	NVPNe25VTnWwY4Tpc44hSXO\|YYm=	NXjiN5MzOTEEoN88UeKh	NFm3cpczPCCq		M2raTYlvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:\|cHjvdplt[XSrb36gc4YheDV\|	NIPPcGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mk[yO\|I6PCd-MkK2NlczQTR:L3G+
IMR-32	M4jiSGZ2dmO2aX;uJGF{e2G7	MXmxNOKh\|ryPwrC=	MknKNlQhcA>?		M1voc4lvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:\|cHjvdplt[XSrb36gc4YheDV\|	MmLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ4MkeyPVQoRjJ{NkK3Nlk1RC:jPh?=
A549	MXLGeY5kfGmxbjDBd5NigQ>?	MlHmNVDDqM7:TdMg	M4PUdlEhcA>?		MXfzeZBxemW\|c3XzJG5idm9vQ3:tbY5lfWOnZDDwOVMh[WOldX31cIF1cW:w	NFW3WZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW1PVMzOSd-MkK1OVk{OjF:L3G+
T47D	NGfibVJHfW6ldHnvckBCe3OjeR?=	M1jiWlIxyqCvTR?=	NU\4ZlExOjRiaB?=	NV3vXGtHTE2VTx?=	M33SRpBz\X[nboTzJGlTNWmwZIXj[YQh\GWpcnHkZZRqd25ib3[gTe67Ss7z	MorhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzNES4NFUoRjJzMUS0PFA2RC:jPh?=
A29 MEF	M4PLO2Z2dmO2aX;uJGF{e2G7	NV;OeGVvOTEEoN88UeKh	M3KwV\|Fp		M4XyN4Jtd2Otc9MgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDa4SgZZQhW2W{NEezxsA>	NWPvW3FLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwOVM4QDFpPkKwNFU{PzhzPD;hQi=>
MDA-MB-453	Ml7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLGbHM2NTRyIN88US=>	NULEUXc2PzJiaB?=		NI[1T\|hKSzVyIH;mJFExKM7:TR?=	NXftbmdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwOVM4QDFpPkKwNFU{PzhzPD;hQi=>
PC-3	MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHqVGI2NTRyIN88US=>	NVy1VnpmPzJiaB?=		MYrJR\|UxKG:oIEGwJO69VQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB3M{e4NUc,OjByNUO3PFE9N2F-
U2OS	M32xcGZ2dmO2aX;uJIF{e2G7				NWDWN\|F1UW6qaXLpeIlwdiCxZjDBWG0hcW5iaIXtZY4hXTKRUzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHB3MzDwbI9{eGixconsZZRqd25iYYSgV4VzOTVicnXzbYR2\SxiSVO1NEA:KDBwMkWg{txONg>?	M37nZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkOyPVY2Lz5{Nk[zNlk3PTxxYU6=
MCF7	MYPGeY5kfGmxbjDhd5NigQ>?		MmH2NUBpeg>?		MVnJcohq[mm2aX;uJI9nKEGWTTDrbY5ie2ViaX6gbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiBzIHjyJIJ6KGmvbYXuc4ZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvOyEQvF2u	NGTj[mY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nk[zNlk3PSd-Mk[2N\|I6PjV:L3G+
BJ	M3\DO2Z2dmO2aX;uJIF{e2G7	NULVfmFNOTBidV2=	NIjmNJYyOCCmYYnz		NUDicZdTW3WycILld5Nqd25ib3[gd4Vv\XOlZX7j[UBqdiCqdX3hckBDUiClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDj[YxtKG63bXLldkBifCBzMDD1UUBi\nSncjCxNEBl[Xm\|IHL5JJNmdmW\|Y3XuZ4UhemW4ZYLzZYwh[XO\|YYm=	M2T5dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{[3NFg2Lz5zNke2O\|A5PTxxYU6=
BJ	MYPGeY5kfGmxbjDhd5NigQ>?	NFLuTnkyOCC3TR?=	M2XK[FExKGSjeYO=		NHvkUnJKdmirYnn0bY9vKG:oIHH0ZZhq[SC2ZXzhcodq\WO2YYPpZU1ufXSjdHXkJIlvKGi3bXHuJGJLKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHPlcIwhdnWvYnXyJIF1KDFyIIXNJIFnfGW{IEGwJIRigXNiYomgd4Vv\XOlZX7j[UBz\X[ncoPhcEBie3OjeR?=	M{jub\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{[3NFg2Lz5zNke2O\|A5PTxxYU6=
MCF7	MXHGeY5kfGmxbjDhd5NigQ>?	M4rOWVExKHWP	MnmyNVAhdWmwcx?=		MnrjV4Vve2m2aYrheIlwdiCxZjDpcoZz[XKnZD3pcoR2[2WmIFTORUBl[W2jZ3WgbY4hcHWvYX6gUWNHPyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ49td267IH\vdo1ifGmxbjDheEAyOCC3TTDwdoV1emWjdHXkJIZweiBzMDDtbY5{KG[xbHzve4VlKGK7IHnydoFlcWG2aX;uJIZweiB2IHjyd{Bu\WG\|dYLl[EBi\nSncjCxNEBl[Xm\|IHL5JINzgXO2YXygeolwdGW2IIP0ZYlvcW6pIHHuZYx6e2m\|	NUnKco5RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2N\|I6PjVpPkK2OlMzQTZ3PD;hQi=>
SK-N-MC	M3PBOpFJXFNiYYPzZZk>				Mo\NdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MlnkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT(Ser473) / p-AKT(Thr308); PubMed: 22739265 Chin J Cancer Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖 PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; PubMed: 22739265 Chin J Cancer ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤 ATM-S1981 / ATM / p-p53(S15) / p53 ; PubMed: 20639198 J Biol Chem Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖 p21 / p27 / p53 ; PubMed: 20177072 J Biol Chem HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.	22739265 20639198 20177072
Immunofluorescence	p-S824 KAP1 / ZEBRA ; PubMed: 28249048 PLoS Pathog HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.	28249048

In vivo

Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. ^[3]

Protocol

Kinase Assay: ^[1]	- Collapse Purified enzyme assays: ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl₂, 250 mM KCl, 500 μM EDTA, 100 μM Na₃VO₄, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH₂-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl₂, 2 mM MnCl₂, 50 μM Na₃VO₄, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research: ^[1]	- Collapse Cell lines: U2OS cells Concentrations: 10 μM Incubation Time: 2 hours Method: U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m²) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells Dosages: 10 μM Administration: -- (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	33 mg/mL (83.44 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+40%PEG300+5%Tween80+50%ddH2O For best results, use promptly after mixing.	3.95 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download KU-55933 (ATM Kinase Inhibitor) SDF

Molecular Weight	395.49
Formula	C₂₁H₁₇NO₃S₂
CAS No.	587871-26-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1COCCN1C2=CC(=O)C=C(O2)C3=C4C(=CC=C3)SC5=CC=CC=C5S4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Pan ATM/ATR Inhibitor

CGK 733 : Dual ATM/ATR inhibitor, IC50=~200 nM.
Most Potent ATM/ATR Inhibitor

AZ20 ^New : ATR, IC50=5 nM.
ATM/ATR Inhibitor in Clinical Trial

BEZ235 (NVP-BEZ235, Dactolisib) : Phase II for Advanced Endometrial Carcinoma.
Newest ATM/ATR Inhibitor

VE-822 ^New : ATR inhibitor with IC50 of 19 nM.

Related ATM/ATR Products

Ceralasertib (AZD6738) ^New

Ceralasertib (AZD6738) is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
Dorsomorphin (Compound C) ^New

Dorsomorphin (Compound C, BML-275) is a potent, reversible, selective AMPK inhibitor with K_i of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy.
VE-821

VE-821 is a potent and selective ATP competitive inhibitor of ATR with K_i/IC50 of 13 nM/26 nM in cell-free assays, shows inhibition of H2AX phosphorylation, minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3Kγ.
KU-60019

KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays, 270- and 1600-fold more selective for ATM than DNA-PK and ATR,and is a highly effective radiosensitizer.

Features:Improved analog of KU-55933, and is more effective at blocking ATM-mediated DDR events.
Berzosertib (VE-822)

Berzosertib (VE-822, VX970, M6620) is an ATR inhibitor with IC50 of 19 nM in HT29 cells.

Features:VE-822 is a highly selective and potent derivative of the ATR inhibitor VE-821.
Chloroquine diphosphate

Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. Chloroquine is also an inhibitor of toll-like receptors (TLRs).
AZ20

AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.

Features:AZ20 is the first reported inhibitor of ATR protein kinase demonstrating tumor growth inhibition in vivo.
CP-466722

CP-466722 is a potent and reversible ATM inhibitor, does not affect ATR and inhibits PI3K or PIKK family members in cells.
ETP-46464

ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

Features:Selective ATR inhibitor and particularly toxic to p53-deficient cancer cells. Often used as a pharmacologic probe due to its ideal pharmacological properties.

Choose Your Country or Region

By Signaling Pathways

By product type

KU-55933 (ATM Kinase Inhibitor)